Patient satisfaction with health status in rheumatoid arthritis based on remote assessment: a pilot OPTIMA study (Patient-reported Outcomes, Severity and Medical care in Arthritis)

Leading Russian and international experts recognize the necessity of incorporating patient-reported outcomes (PROs) into the dynamic monitoring of rheumatoid arthritis (RA) patients. An integral indicator of general well-being and treatment satisfaction is the Patient Acceptable Symptom State (PASS).
Objective: To assess patient satisfaction with their health status and treatment outcomes in RA and to evaluate its relationship with key disease manifestations through remote PROs assessment.
Material and methods. From January 2023 to November 2024, an online survey was conducted involving 2,115 RA patients (88.3% women, mean age 46.4±13.9 years, median disease duration 6 [3; 13] years). The survey assessed demographics, therapy, PASS, and PROs (pain, fatigue, anxiety, depression, daily activity limitations, patient global assessment [PGA], using a numerical rating scale [NRS], 0–10). Among respondents, 80% were receiving conventional synthetic disease-modifing antirheumatic drugs (DMARDs), 23.8% biologic DMARDs (bDMARDs) or Janus kinase inhibitors (JAKi). Glucocorticoids (GCs) were used by 39.7%, and nonsteroidal anti-inflammatory drugs (NSAIDs ) by 67.9% of patients.
Results and discussion. A positive assessment of their health status (PASS+) was reported by 45.8% of patients. Mean NRS scores were: pain – 5.6±2.7, fatigue – 6.2±2.7, PGA – 5.5±2.5, median anxiety – 5 [3; 8], depression – 5 [2; 7], daily activity limitations – 5 [3; 7]. Dissatisfaction (PASS-) was associated with male gender, moderate (≥4) or high (≥7) NRS PRO scores, and the use of GCs and NSAIDs. bDMARD and JAKi therapy showed an inverse association with PASS-. A binary logistic regression model was developed to predict PASS- in RA patients with an accuracy of up to 71%. ROC curve analysis revealed a threshold value of the logistic function P at 49.6%, area under the curve (AUC) – 0.740 (95% CI 0.718–0.762), model sensitivity – 82%, specificity – 60%.
Conclusion. Fewer than half of RA patients were satisfied with their health status when assessed remotely. PASS is closely associated with PROs and may serve as an integral indicator of health status and treatment satisfaction in RA.

1. Van Tuyl LH, Sadlonova M, Hewlett S, et al. The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Ann Rheum Dis. 2017 May; 76(5):855-861. doi: 10.1136/annrheumdis-2016-209835. Epub 2016 Nov 30.

2. Michaud K, Pope J, van de Laar M, et al. Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthrtis. Arthritis Care Res (Hoboken). 2021 Nov;73(11):1606-1616. doi: 10.1002/acr.24369. Epub 2021 Sep 9.

3. Ishida M, Kuroiwa Y, Yoshida E, et al. Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Mod Rheumatol. 2018 Sep;28(5): 789-799. doi: 10.1080/14397595.2017.1416940. Epub 2018 Jan 11.

4. Ishiguro N, Dougados M, Cai Z, et al. Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials. Mod Rheumatol. 2018 Nov;28(6):950-959. doi: 10.1080/14397595.2017.1422232. Epub 2018 Feb 2.

5. Patient's reported outcomes – a new philosophy for analyzing the effectiveness of therapy in immunoinflammatory diseases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(5):121-127. (In Russ.). doi: 10.14412/1996-7012-2021-5-121-127

6. Tubach F, Ravaud P, Beaton D, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol. 2007 May;34(5):1188-93.

7. Puyraimond-Zemmour D, Etcheto A, Fautrel B, et al. Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 Patients. Arthritis Care Res (Hoboken). 2017 Oct;69(10):1504-1509. doi: 10.1002/acr.23176. Epub 2017 Sep 6.

8. Tubach F, Ravaud P, Martin-Mola E, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012 Nov; 64(11):1699-707. doi: 10.1002/acr.21747.

9. Salaffi F, Carotti M, Gutierrez M, et al. Patient Acceptable Symptom State in SelfReport Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care. Biomed Res Int. 2015; 2015:930756. doi: 10.1155/2015/930756. Epub 2015 Jun 18.

10. Safikhani M, Rezaieyazdi Z, Khodashahi M. Evaluation of assessable telemedicine in patients with rheumatoid arthritis: A systematic review. Int J Rheum Dis. 2024 Jan;27(1): e15007. doi: 10.1111/1756-185X.15007.

11. Arumalla N, Chan CKD, Gibson M, et al. The clinical impact of electronic patient-reported outcome measures in the remote monitoring of inflammatory arthritis: a systematic review and meta-analysis. Arthritis Rheumatol. 2023 Nov;75(11):1892-1903. doi: 10.1002/art.42559. Epub 2023 Sep 18.

12. Barlas N, Barlas SB, Basnyat S, Adalier E. Telemedicine in Rheumatoid Arthritis: A Review of the PubMed Literature. Mediterr J Rheumatol. 2023 Mar 31;34(1):16-23. doi: 10.31138/mjr.34.1.16.

13. Potapova AS, Karateev AE, Polishchuk EYu, et al. Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study. Nauchno-prakticheskaya revmatologiya. 2024;62(5):535-541. (In Russ.).

14. Heiberg T, Kvien TK, Mowinckel P, et al. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Jul;67(7):967-71. doi: 10.1136/ard.2007.077503. Epub 2007 Oct 26.

15. Katchamart W, Narongroeknawin P, Suppa-Udom B, et al. Factors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritis. Clin Rheumatol. 2020 Mar;39(3):779-786. doi: 10.1007/s10067-019-04860-3. Epub 2019 Dec 10.

16. Karateev AE, Polishchuk EYu, Potapova AS, Amirdzhanova VN. A small secret of big rheumatology. Nauchno-Prakticheskaya Revmatologia. 2024;62(4):335-341. (In Russ.).

17. Karateev AE, Polishchuk EYu, Potapova AS, et al. The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients. Nauchno-prakticheskaya revmatologiya. 2022; 60(2):149-156. (In Russ.).

18. Kvamme MK, Kristiansen IS, Lie E, Kvien TK. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2010 Jan; 37(1):26-31. doi: 10.3899/jrheum.090449. Epub 2009 Dec 1.

19. Vorobyeva LD, Korotaeva TV, Loginova EYu, et al. Impact of tofacitinib on patient-reported outcomes in patients with psoriatic arthritis. Data from the real clinical practice. Nauchnoprakticheskaya revmatologiya. 2022;60(3): 334-340. (In Russ.).

20. Gwinnutt JM, Hyrich KL, Lunt M, et al. RAMS Co-Investigators. Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as 'satisfactory'. Rheumatology (Oxford). 2020 Aug 1;59(8):1853-1861. doi: 10.1093/rheumatology/kez497.

21. Duarte C, Santos E, Kvien TK, et al. Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors. Joint Bone Spine. 2021 Jan;88(1):105071. doi: 10.1016/j.jbspin.2020.09.003. Epub 2020 Sep 10.

22. Stocker PH, Jasper MH, Kahlow B, et al. Depression as a major determinant of PASS (Patient's Acceptable Symptoms State) in rheumatoid arthritis: a cross-sectional study in Brazilian patients. Rev Assoc Med Bras (1992). 2022 Aug;68(8):995-999. doi: 10.1590/1806-9282.20220600.

23. Garufi C, Mancuso S, Ceccarelli F, et al. PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors. Reumatismo. 2025 Feb 13;77(1). doi: 10.4081/reumatismo.2024.1725. Epub 2024 Nov 5.